Success Metrics

Clinical Success Rate
71.4%

Based on 5 completed trials

Completion Rate
71%(5/7)
Active Trials
4(29%)
Results Posted
40%(2 trials)
Terminated
2(14%)

Phase Distribution

Ph phase_1
1
7%
Ph phase_2
9
64%
Ph phase_3
4
29%

Phase Distribution

1

Early Stage

9

Mid Stage

4

Late Stage

Phase Distribution14 total trials
Phase 1Safety & dosage
1(7.1%)
Phase 2Efficacy & side effects
9(64.3%)
Phase 3Large-scale testing
4(28.6%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

71.4%

5 of 7 finished

Non-Completion Rate

28.6%

2 ended early

Currently Active

4

trials recruiting

Total Trials

14

all time

Status Distribution
Active(4)
Completed(5)
Terminated(2)
Other(3)

Detailed Status

Completed5
Recruiting4
unknown3
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
14
Active
4
Success Rate
71.4%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (7.1%)
Phase 29 (64.3%)
Phase 34 (28.6%)

Trials by Status

terminated214%
unknown321%
recruiting429%
completed536%

Recent Activity

4 active trials
Showing 5 of 14
completedphase_3

Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix

NCT03556839
recruitingphase_2

Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation

NCT05609578
recruitingphase_2

Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma

NCT06318286
recruitingphase_3

9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer

NCT06592326
recruitingphase_2

A Phase II Study of Triple-negative Breast Cancer Brain Metastases.

NCT04303988
View all 14 trials

Clinical Trials (14)

Showing 14 of 14 trials
NCT03556839Phase 3

Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix

Completed
NCT05609578Phase 2

Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation

Recruiting
NCT06318286Phase 2

Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma

Recruiting
NCT06592326Phase 3

9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer

Recruiting
NCT04303988Phase 2

A Phase II Study of Triple-negative Breast Cancer Brain Metastases.

Recruiting
NCT04864782Phase 2

QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer

Terminated
NCT04297995Phase 2

Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck Tumors

Unknown
NCT05446883Phase 3

QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer

Unknown
NCT04861948Phase 1

IBI188 Combination Therapy in Solid Tumors

Terminated
NCT02383966Phase 3

Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Participants With Head and Neck Cancer

Completed
NCT04750083Phase 2

HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

Unknown
NCT01496742Phase 2

A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer

Completed
NCT01519804Phase 2

A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer

Completed
NCT00971932Phase 2

Study of Cetuximab in Combination With Chemotherapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Completed

All 14 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
14